Existing investors include BioGeneration Ventures
Existing investors include BioGeneration Ventures
Ghent, Belgium – Confo Therapeutics, a pioneering company in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), has successfully closed a EUR 60 million Series B financing round. This funding was spearheaded by Ackermans & van Haaren (AvH) and saw participation from new investors, including Driehaus Capital Management and Quest for Growth, alongside existing supporters like BioGeneration VenturesBioGeneration Ventures, Capricorn Health-tech Fund, and others.
Taxfix
Taxfix
Taxfix is a well-funded tech startup in the heart of Berlin. It is our mission to make tax declaration easy! We believe that everybody, regardless of their income, deserves to get the maximum out of their tax returns. Taxfix allows everyone to file taxes in 25 minutes on the mobile phone, without any knowledge about taxes, no stress, and no forms. You will find a tax-language easy to understand and a chat-like interface to guide you through the process. We would love to hear your feedback! (hallo@taxfix.de) We are looking for talented people to join our international team in Europe's No. 1 tech hub. If you want to be part of Taxfix, please have a look at our open positions at https://taxfix.recruitee.com/ or reach out to us at jobs@taxfix.de https://www.facebook.com/taxfix.de/ https://twitter.com/taxfix_de https://meritocracy.is/en/taxfix https://stackoverflow.com/jobs/companies/taxfix
Taxscouts
Taxfix acquires Taxscouts
Taxfix accelerates expansion and is now operating in four of the largest European financial markets: Germany, the UK, Spain, and Italy. TaxScouts' geographical reach and market segments complement Taxfix's proven services.
Deactivated Topic
Confo Therapeutics Secures EUR 60M Series B Funding to Advance GPCR Drug Development
Ghent, Belgium – Confo Therapeutics, a pioneering company in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), has successfully closed a EUR 60 million Series B financing round. This funding was spearheaded by Ackermans & van Haaren (AvH) and saw participation from new investors, including Driehaus Capital Management and Quest for Growth, alongside existing supporters like BioGeneration Ventures, Capricorn Health-tech Fund, and others.
The fresh capital will support Confo Therapeutics' mission to push two proprietary programs through Phase 1 clinical trials and advance two additional programs to Investigational New Drug (IND) approval, with a particular focus on molecules targeting GPR75 for obesity treatment. Additionally, the company aims to broaden its research and development efforts, particularly in discovering new therapeutic candidates for rare endocrine diseases and developing GPCR-targeting small molecules and agonistic antibodies.
Cedric Ververken, CEO of Confo Therapeutics, highlighted the significance of this investment, stating, "With the backing from our experienced international investor syndicate, we plan to accelerate our ambitious development pipeline, including potential new therapies for severe rare endocrine diseases and next-generation obesity drugs."
Jeroen Vangindertael, Investment Manager at AvH, expressed his enthusiasm about Confo's progress and strategy, emphasizing the company's proprietary platform and its potential to generate novel medicines through the discovery of agonistic antibodies directed at GPCRs. As part of the investment deal, Dr. Vangindertael will join Confo’s Board of Directors, and Alex Munns from Driehaus will become a Board Observer.
Dieter Weinand, Independent Chairman of the Board at Confo Therapeutics, welcomed the new investors and expressed gratitude for their support, noting that the continued backing would enable the company to focus on advancing therapeutic candidates for patients with metabolic and endocrine disorders.
Confo Therapeutics continues to leverage its unique discovery platform that utilizes conformation-specific ConfoBodies® to develop small molecules and antibodies aimed at transforming therapeutic outcomes for patients. The company remains committed to addressing unmet medical needs in metabolic and endocrine diseases through innovative GPCR-directed therapies.
Deactivated Topic
Confo Therapeutics Series B
Belgian GPCR specialist Confo Therapeutics NV has raised €60m in an Series B financing round led by Ackermans & van Haaren to advance clinical development of two clinical programmes and preclinical candidates to treat rare endocrine diseases and obesity.